
Quarterly report 2026-Q1
added 05-13-2026
Milestone Scientific EBITDA 2011-2026 | MLSS
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Milestone Scientific
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.62 M | -6.72 M | -7.04 M | -8.76 M | -7.3 M | -7.41 M | -3.74 M | -5.58 M | -4.66 M | -6.35 M | -2.96 M | -694 K | 1.18 M | -425 K | -1.12 M | -656 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.18 M | -8.76 M | -4.24 M |
Quarterly EBITDA Milestone Scientific
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -809 K | -1.11 M | -1.47 M | -1.98 M | - | -1.46 M | -1.77 M | -1.45 M | - | -1.49 M | -2.26 M | -1.33 M | - | -2 M | -2.87 M | -1.9 M | - | -1.96 M | -2.86 M | -963 K | - | -1.46 M | -3.15 M | -1.57 M | - | -921 K | -1.08 M | -792 K | - | -4.2 M | -1.18 M | -1.74 M | - | -1.25 M | -1.52 M | -491 K | - | -1.5 M | -1.97 M | -921 K | - | -815 K | -1.4 M | -65.4 K | - | -150 K | 54.5 K | 333 K | - | 449 K | 1.47 M | 172 K | - | 66.1 K | -43.6 K | -228 K | - | -524 K | -251 K | -116 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.47 M | -4.2 M | -1.14 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical instruments industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
37.7 K | - | - | $ 810 M | ||
|
The Cooper Companies
COO
|
1.06 B | $ 67.88 | 0.55 % | $ 13.5 B | ||
|
Glaukos Corporation
GKOS
|
-162 M | $ 126.81 | 2.05 % | $ 7.25 B | ||
|
Luminex Corporation
LMNX
|
72.9 M | - | - | $ 1.75 B | ||
|
Intuitive Surgical
ISRG
|
3.55 B | $ 411.06 | -0.45 % | $ 147 B | ||
|
Akers Biosciences, Inc.
AKER
|
-12.3 M | - | -9.52 % | $ 20.6 M | ||
|
Alcon
ALC
|
580 M | $ 66.85 | 0.51 % | $ 40.4 B | ||
|
ICU Medical
ICUI
|
244 M | $ 142.2 | -0.46 % | $ 3.5 B | ||
|
iRhythm Technologies
IRTC
|
-36.7 M | $ 113.65 | 0.87 % | $ 3.64 B | ||
|
LeMaitre Vascular
LMAT
|
78.3 M | $ 91.96 | -0.41 % | $ 2.08 B | ||
|
Antares Pharma, Inc.
ATRS
|
16.2 M | - | - | $ 955 M | ||
|
Repro Med Systems
KRMD
|
-2.16 M | $ 4.0 | - | $ 185 M | ||
|
Cantel Medical Corp.
CMD
|
123 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
33.9 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
518 M | - | -0.05 % | $ 10.3 B | ||
|
Microbot Medical
MBOT
|
-14.7 M | $ 1.78 | -2.2 % | $ 81.5 M | ||
|
Masimo Corporation
MASI
|
-164 M | $ 179.95 | - | $ 9.59 B | ||
|
Ekso Bionics Holdings
EKSO
|
-11.8 M | - | - | $ 28.6 M | ||
|
Varian Medical Systems, Inc.
VAR
|
60 M | - | -0.02 % | $ 16.3 B | ||
|
Merit Medical Systems
MMSI
|
308 M | $ 66.53 | -0.54 % | $ 3.94 B | ||
|
electroCore
ECOR
|
-12.7 M | $ 10.25 | 0.69 % | $ 87 K | ||
|
Envista Holdings Corporation
NVST
|
332 M | $ 24.6 | 0.41 % | $ 4.13 B | ||
|
Haemonetics Corporation
HAE
|
268 M | $ 78.2 | -2.05 % | $ 3.69 B | ||
|
Isoray
ISR
|
-110 M | - | 0.03 % | $ 108 M | ||
|
Utah Medical Products
UTMD
|
12.2 M | $ 67.84 | -2.3 % | $ 220 M | ||
|
STERIS plc
STE
|
1.59 B | $ 207.56 | 0.16 % | $ 20.4 B | ||
|
STAAR Surgical Company
STAA
|
-83.4 M | $ 28.37 | -1.83 % | $ 1.41 B | ||
|
InfuSystem Holdings
INFU
|
25.2 M | $ 9.14 | 0.99 % | $ 189 M | ||
|
Teleflex Incorporated
TFX
|
192 M | $ 130.48 | 1.14 % | $ 5.82 B | ||
|
West Pharmaceutical Services
WST
|
756 M | $ 328.82 | -0.46 % | $ 23.8 B | ||
|
Pulse Biosciences
PLSE
|
-76.5 M | $ 24.37 | -9.37 % | $ 1.64 B | ||
|
DENTSPLY SIRONA
XRAY
|
-70 M | $ 10.09 | -0.49 % | $ 2.01 B | ||
|
Retractable Technologies
RVP
|
-13.4 M | $ 0.7 | -0.03 % | $ 21 M | ||
|
Pro-Dex
PDEX
|
11.9 M | $ 62.2 | -1.14 % | $ 205 M | ||
|
Predictive Oncology
POAI
|
-181 M | - | - | $ 31.1 M | ||
|
BioLife Solutions
BLFS
|
-14.3 M | $ 26.1 | -1.88 % | $ 1.25 B | ||
|
Stereotaxis
STXS
|
-21.5 M | $ 1.84 | 1.1 % | $ 167 M | ||
|
Baxter International
BAX
|
673 M | $ 20.86 | 1.81 % | $ 10.7 B | ||
|
ResMed
RMD
|
1.16 B | $ 194.78 | 1.24 % | $ 28.5 B | ||
|
AtriCure
ATRC
|
2.64 M | $ 28.79 | 1.34 % | $ 1.37 B | ||
|
Harvard Bioscience
HBIO
|
-46.8 M | $ 6.08 | -8.43 % | $ 270 M | ||
|
NeuroMetrix
NURO
|
-8.69 M | - | 5.05 % | $ 9.02 M | ||
|
AngioDynamics
ANGO
|
-14.2 M | $ 12.1 | 0.17 % | $ 494 M | ||
|
Becton, Dickinson and Company
BDX
|
5.04 B | $ 146.24 | -0.75 % | $ 42.1 B | ||
|
Nephros
NEPH
|
1.29 M | $ 3.34 | 0.3 % | $ 35.4 M | ||
|
OraSure Technologies
OSUR
|
-61.8 M | $ 4.18 | -0.24 % | $ 307 M | ||
|
Repligen Corporation
RGEN
|
134 M | $ 130.59 | -2.06 % | $ 7.34 M |